J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

SAN FRAN­CIS­CO — John­son & John­son is adding to Big Phar­ma’s love for an­ti­body-drug con­ju­gates with a $2 bil­lion cash deal to swoop up Am­brx Bio­phar­ma.

The deal was an­nounced Mon­day morn­ing as the an­nu­al JP Mor­gan Health­care Con­fer­ence gets un­der­way along­side two oth­er ac­qui­si­tions: Mer­ck-Har­poon and No­var­tis-Ca­lyp­so. The trio of ac­qui­si­tions fol­lows a deal-heavy De­cem­ber as the in­dus­try ex­pects Big Phar­ma to start spend­ing its trove of cash to shore up its pipelines as end-of-decade patent ex­pi­ra­tions loom.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER